Praxis Precision (PRAX) announced results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients ...

BOSTON, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

I maintain a Hold rating on Praxis Precision Medicines, Inc., driven by positive open-label Radiant data for vormatrigine in epilepsy but tempered by clinical risks. Vormatrigine achieved a 56.3% ...

A study investigating the functional connectivity of the praxis network in patients in the early stages of Parkinson’s disease (PD) found that dopaminergic therapy may normalize praxis abilities and ...

On Tuesday, Truist Securities maintained a Buy rating and a $150.00 stock price target for Praxis Precision Medicines Inc. (NASDAQ: PRAX), following the announcement of positive results from their ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Shares of Praxis Precision Medicines, Inc. PRAX were down 78.1% on Monday after the company announced disappointing data from the phase II/III Aria study that evaluated its pipeline candidate, ...